Gilead Sciences (NASDAQ:GILD) has had a great year so far, with Sovaldi (its hepatitis c cure) turning in an incredible $2.3 billion in sales in its first full quarter on the market. Sovaldi's performance has helped fuel Gilead's 18% price gain year-to-date.
So it's no surprise that investors should be watching for Sovaldi sales when Gilead announces earnings later this month. But in the video below, health care analysts Michael Douglass and David Williamson lay out the company's other long-term opportunities and how they matter for Gilead.
Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. The Motley Fool owns shares of Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.